Response to 'Cure for Mantle Cell Lymphoma Within Reach'Response to 'Cure for Mantle Cell Lymphoma Within Reach'

Researchers not involved in the current research contest the characterization of bendamustine and rituximab as a "salvage" therapy, among other concerns. Letters to the Editor
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

Condition:   Precursor Cell Lymphoblastic Leukemia-lymphoma Intervention:   Drug: Ixazomib Sponsor:   Millennium Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Follicular Lymphoma Intervention:   Drug: REGN1979 Sponsor:   Regeneron Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(CNN) — Many women have breast implants with no serious complications, but there have been cases where women suffer pain and fatigue, among other health problems. Now, the US Food and Drug Administration plans to hold a meeting to take a closer look at such cases and put breast implant safety under a microscope. The FDA will convene a meeting of the Medical Devices Advisory Committee’s General and Plastic Surgery Devices Panel on Monday and Tuesday to discuss and make recommendations relating to the risks and benefits of breast implants. The meeting, which will be open to the public, comes just days after the F...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News CNN Source Type: news
Publication date: Available online 23 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Stefano Molica, Diana Giannarelli, Emili MontserratAbstractBackgroundChronic lymphocytic leukemia (CLL) patients who achieve undetectable minimal residual disease (U-MRD) (i.e.,
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
a Pro Although Hodgkin lymphoma (HL) is highly curable with first-line therapy, relapses occur in approximately 10–20% of patients with early stage disease and 30–40% of patients with advanced stage disease. The standard approach for relapsed or refractory disease is salvage therapy, followed by consolidation with high dose therapy and autologous stem cell transplant (ASCT). Patients who achieve a complete response to salvage therapy prior to ASCT have better outcomes, thus recent studies have focused on incorporating newer agents in this setting. Major challenges in the management of relapsed patie...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This study aimed to investigate the value of PTEN, NF-κB, WWP2, p53 and c-Myc expressions in distinguishing B cell lymphomas from reactive follicular hyperplasia (RFH), and their abilities to discriminate different B cell lymphoma subtypes. Lymphoma tissue samples were obtained from 30 follicular lymphoma (FL) patients, 30 germinal center B-cell like (GCB) diffuse large B cell lymphoma (DLBCL) patients, 30 non-GCB DLBCL patients and 30 Burkitt's lymphoma (BL) patients. And hyperplasia tissue samples were obtained from and 30 RFH patients. Immunohistochemistry was used to quantify the expressions of PTEN, NF-κB,...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Publication date: Available online 23 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hiroshi Ureshino, Kazuharu Kamachi, Shinya KimuraAbstractMogamulizumab, a defucosylated humanized monoclonal antibody against C–C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more effecacy in relapsed ATL making mogamulizumab a promising therapeutic agent. However, mogamulizumab could increase graft-versus-host disease, resulting in poor survival outcome in allogenic st...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSIONS:: This report describes an extremely rare case of a tracheal IMT, underlying the key role of radiotherapy as adjuvant treatment able to definitively cure IMT, limiting systemic chemotherapy-related toxicity. PMID: 30900517 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Publication date: 1 May 2019Source: Chemico-Biological Interactions, Volume 304Author(s): M.F. Nagoor Meeran, Hasan Al Taee, Sheikh Azimullah, Saeed Tariq, Ernest Adeghate, Shreesh OjhaAbstractThe cannabinoid type 2 receptor (CB2) has recently emerged as an important therapeutic target for cancer as well as cardiovascular diseases. The CB2 receptor downregulation has been reported in solid tumors and cardiovascular diseases, therefore the CB2 receptor activation has been considered as a viable strategy for chemotherapy as well as cardioprotection. Doxorubicin (DOX) is an important drug that continues to be the mainstay of ...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Authors: Bright SA, Byrne AJ, Vandenberghe E, Browne PV, Mcelligott AM, Meegan MJ, Williams DC Abstract The nitrostyrene scaffold was previously identified as a lead target structure for the development of effective compounds targeting Burkitt's lymphoma. The present study aimed to develop these compounds further in haematological malignancies, including chronic lymphocytic leukaemia (CLL). Cellular viability, flow cytometry and lactate dehydrogenase assays, amongst others, were used to examine the effects of nitrostyrene compounds on CLL cells, including a cell line representing disease with poor prognosis (HG‑3...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Cancer & Oncology | Health | Hematology | Lymphoma | Rituxan | Treanda